After TGF-β1 treatment, ESCC cells exhibit decreased expression of epithelial markers and increased expression of mesenchymal markers, of which E-cadherin is down-regulated while N-cadherin and Vimentin are up-regulated. The gene discussed is CDH2; the disease is esophageal squamous cell carcinoma.